Shares of Deciphera Pharmaceuticals (DCPH) have risen by 20% since my August 2019 update called the stock a Buy based on ripretinib's impressive showing in fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST). Targeted oncology has been one of my favored themes to capitalize on in the past and it seemed that expansion potential of this lead drug candidate compounded with potential of pipeline assets was indicative of significant undervaluation.
As the share price took a hit to start 2020 and the company has a key regulatory date approaching in Q3, I feel